Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

Pfizer said the new forecast includes a one-time charge of 20 cents per share related to its recent licensing deal with China ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive surprises than negative ones.